Boehringer Ingelheim
  • About Jardiance
  • About Metabolic
  • Resources
  • Contact
sa
Login

Metabolic

Metabolic

Metabolic

425
million adult people
in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all cases1
 

Safety

CARMELINA study; CArdiovascular and Renal Microvascular outcomE study with LINAgliptin in patients with type 2 diabetes mellitus

icoPDF

CARMELINA study; CArdiovascular and Renal Microvascular outcomE study with LINAgliptin in patients with type 2 diabetes mellitus
CAROLINA Study; CARdiovascular Outcome study of LINAgliptin vs glimepiride in patients with type 2 diabetes

icoPDF

CAROLINA Study; CARdiovascular Outcome study of LINAgliptin vs glimepiride in patients with type 2 diabetes
EMPRISE Study; Empagliflozin real world effectiveness & Safety

icoPDF

EMPRISE Study; Empagliflozin real world effectiveness & Safety
EMPULSE Study; in-hospital intiation of Empagliflozin in patients hosptalized for HF with HFrEF or HFpEF, with or without T2D

icoPDF

EMPULSE Study; in-hospital intiation of Empagliflozin in patients hosptalized for HF with HFrEF or HFpEF, with or without T2D
EMPRISE Study; Empagliflozin real world safety and reduction of acute kidney injury

icoPDF

EMPRISE Study; Empagliflozin real world safety and reduction of acute kidney injury
CARMELINA Study Rational & Background Global Experts Video

02:49

CARMELINA Study Rational & Background Global Experts Video
CARMELINA Study at glance; Linagliptin reassured long-term CV & Kideny safety profile Global Experts Video

03:31

CARMELINA Study at glance; Linagliptin reassured long-term CV & Kideny safety profile Global Experts Video
EMPRISE Study; Empagliflozin real world comparative effictiveness & safety

06:35

EMPRISE Study; Empagliflozin real world comparative effictiveness & safety
Production date: Apr 2020
  • Therapeutic Area
  • Metabolic
  • Respiratory
  • Cardiovascular
  • Angels
  • Resources
  • Videos
  • Clinical studies
  • Site map
  • Terms of use
  • Privacy
  • Contact
  • Change country

© 2010-2021 Boehringer Ingelheim International GmbH. All rights reserved.